Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

Abstract Background NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome of further PRRT cycles in the so called salvage setting in patients after initial r...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: S. Rudisile, A. Gosewisch, V. Wenter, M. Unterrainer, G. Böning, F. J. Gildehaus, W. P. Fendler, C. J. Auernhammer, C. Spitzweg, P. Bartenstein, A. Todica, H. Ilhan
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2019-08-01
Edice:BMC Cancer
Témata:
PRRT
Salvage therapy
NET
SPECT
Dosimetry
Survival
On-line přístup:http://link.springer.com/article/10.1186/s12885-019-6000-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky